Department of Behavioral Neuroscience & Drug Development

Modeling human psychological functions is a fundamental challenge in modern neurobiology and psychopharmacology. This applies both to physiological mental processes (memory, cognitive flexibility, anxiety, activity, optimism, social behavior, communication, mood and drive) and to mental disorders (depression, schizophrenia, substance dependence and behavioral addictions such as gambling).

Some of these functions cannot be studied in humans, therefore laboratory rodent tests are used.

The Department of Behavioral Neuroscience and Drug Development investigates the effects of various substances (new chemical compounds or drugs) on animal behavior. We use a variety of tests intended to evaluate the effectiveness of novel chemical formulations for memory-enhancing properties, anxiolytic activity, the ability to change individual levels of pessimism/optimism in rats and mice or to improve an animal performance on neuropsychological testing. We study rodent ultrasonic communication to assess emotional states in animals, expressed by alarm or euphoric sounds. We also investigate whether a given substance may be useful in the treatment of schizophrenia (e.g. intensifies social behavior, improves cognitive functions), depression (e.g. restores good mood, activates animals), or whether it inhibits addiction. The latter aspect is reflected by the reduced attractiveness of the cage in which the drug or alcohol was administered, or an inhibition of rats’ propensity to press the lever in the 'one-armed bandit' model.

The purpose of our research is to understand how chemicals modulate the behavior of laboratory animals. Our research is designed to develop new, effective drugs for psychiatric disorders and to understand how known drugs used in psychiatry affect the brain. The ultimate goal is to develop new therapies for mental illnesses.

Research methods

- memory tests: new object recognition, Morris water maze, passive and active avoidance, Skinner instrumental cages
- neuropsychological tests: cognitive flexibility (ASST), attention (5-CSRTT)
- anxiety tests: Vogel conflict test, elevated 'plus' maze, four-plates test, open field test
- activity tests: automatic actometers, open field test
- ambiguous-cue interpretation test to measure cognitive judgement bias (optimism / pessimism)
- social interactions and social preferences tests
- system for recording, analyzing and emission ultrasonic vocalizations
- tests to assess antidepressant effects of compounds: forced swim test, sucrose preference
- models of antipsychotic drug action: sensorimotor gating test (PPI), social communication test
 - models of addiction: conditional place preference and aversion test, instrumental 'one-armed bandit' gambling model and Iowa test

The most important recent discoveries
- we have shown that serotonin type 6 and 7 receptors may be responsible for some of the antipsychotic effects of drugs used in the treatment of schizophrenia (e.g. Nikiforuk et al. Effects of the selective 5-HT7 receptor antagonist SB-269970, and amisulpride on ketamine-induced schizophrenia like deficits in rats).

- using the cognitive bias test we have demonstrated in that rats that emit positive ultrasound vocalizations are optimistic (Ryguła et al. Laughing rats are optimistic).

See Wikipedia for more information about our research.

Our former students:

Adamcio Bartek, PhD           2001-2004
Bobula Bartosz, PhD            
Fijał Katarzyna, PhD             2009-2013
Galoch Zdzisław, PhD          1998-1999
Jamroży Małgorzata, M.Sc.  2006-2007
Kozela Ewa, PhD                   1998-2006
Kos Tomasz                           2003-2017
Krawczyk Martyna, M.Sc.     2004-2007
Kubik Jakub, M.Sc.                 2012-2014
Łopuch Sylwia, PhD              2008-2009
Pluta Helena, M.Sc.               2012-2013
Magalas Zofia, PhD               2000-2001
Rafa Dominik, M.Sc.              2010-2017
Ryguła Rafał, PhD                  1999-2001
Ryguła Rafał, PhD                  2013-2017
Schneider Tomasz, PhD        2004-2006
Wesołowska Anna, PhD        2007-2008

More publications
  • , Agnieszka Potasiewicz, PhD

  • The effects of positive allosteric modulators of alpha7 nicotinic acetylcholine receptors on complex cognitive processes, Agnieszka Nikiforuk, PhD
    α7 nicotinic acetylcholine receptors (α7-nAChRs) play important role in the regulation of complex cognitive functions which may be impaired in a number of psychiatric disorders. Moreover, it has been suggested that the α7-nAChRs may be implicated in the pathogenesis of schizophrenia. Therefore, in recent years, α7-nAChRs arouse a great interest as a target for the development of pharmacological treatment of cognitive dysfunctions in schizophrenia. The activity of α7-nAChR can be modulated be either orthosteric agonists or positive allosteric modulators (PAMs). Despite numerous preclinical evidences, the procognitive action of direct α7-nAChR agonist has not been conclusively confirmed in patients with schizophrenia. Allosteric modulation is thought to be associated with more favourable and more specific action. Hence, α7-nAChR PAMs may represent more promising tool. While several α7-nAChR PAMs have been recently developed, their behavioural effects, including their potential impact on cognitive processes, have not been yet extensively characterised. Our research hypothesis is based on the presumption that the action of PAMs may differ from the effects induced by orthosteric receptor activation. It is suggested by PAM-induced retardation of rapid desensitization, a fundamental feature of α7-nAchR. Therefore, the aim of the proposed project is to examine the effects of α7-nAChR PAM in comparison to orthosteric agonists in animal tasks assessing cognitive domains that are important from the perspective of cognitive deficits encountered in schizophrenia (e.g., executive functions, attention, and working memory).
  • , Professor Piotr Popik, PhD


Professor Piotr Popik, PhD

Phone number: +48 12 6623375